Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

the EUMDS Registry Participants

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1745-1750
Number of pages6
JournalLeukemia
Volume35
Issue number6
DOIs
StatePublished - Jun 2021
Externally publishedYes

Funding

FundersFunder number
149Blackpool Victoria Hospital
150Royal Bournemouth Hospital
151Bradford Royal Infirmary
154Harrogate District Hospital
155Huddersfield Royal Infirmary
157Leeds Teaching Hospitals
158Christie Hospital
160Northampton General Hospital
161City Hospital
162John Radcliffe Hospitals NHS Trust
164Royal Cornwall Hospital
167York Hospital
Amgen Limited
Cilag-Janssen
EUMDS
Jazz
Novartis Pharmacy B.V. Oncology Europe
AMGEN
Bristol-Myers Squibb
Pfizer
Astellas Pharma US
Novartis
Gilead Sciences
Alexion Pharmaceuticals
Celgene
Meso Scale Diagnostics
Boehringer Ingelheim
Horizon 2020 Framework Programme634789
Cilag

    Cite this